• Hyperlipoproteinemias

Evkeeza Generic Name & Formulations

General Description

Evinacumab-dgnb 150mg/mL; soln for IV infusion after dilution; preservative-free.

Pharmacological Class

Angiopoietin-like 3 (ANGPTL3) inhibitor.

How Supplied

Single-dose vial (2.3mL, 8mL)—1


Generic Availability


Mechanism of Action

Evinacumab-dgnb inhibition of ANGPTL3 leads to reduction in LDL-C, HDL-C, and triglycerides (TG). It reduces LDL-C independent of the presence of LDL receptor by promoting VLDL processing and clearance upstream of LDL formation. The blockade of ANGPTL3 lowers TG and HDL-C by rescuing lipoprotein lipase and endothelial lipase activities, respectively.

Evkeeza Indications


Adjunct to other LDL-C lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use

Safety and efficacy have not been established for other causes of hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Effects on cardiovascular morbidity and mortality have not been determined.

Evkeeza Dosage and Administration

Adults and Children

<5yrs: not established. Give by IV infusion over 60mins. ≥5yrs: 15mg/kg once monthly (every 4 weeks).


Give by IV infusion over 60mins. Do not mix with other medications or administer other medications concomitantly via the same infusion line.

Evkeeza Contraindications

Not Applicable

Evkeeza Boxed Warnings

Not Applicable

Evkeeza Warnings/Precautions


Discontinue if serious hypersensitivity reactions occur; monitor and treat appropriately. Assess LDL-C when clinically appropriate; effects may be measured as early as 2 weeks after initiation. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers.

Evkeeza Pharmacokinetics


Mean (standard deviation) steady-state trough concentration: 266 (120) mg/L in adults. Mean (standard deviation) Cmax at the end of infusion: 718 (183) mg/L in adults.


Steady-state volume of distribution: ~4.7 L in adults.


The exact pathway through which evinacumab-dgnb is metabolized has not been characterized. As a human monoclonal IgG4 antibody, evinacumab-dgnb is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.


Evinacumab-dgnb elimination is mediated via parallel linear and non-linear pathways. The elimination half-life is a function of serum evinacumab-dgnb concentrations, and is not a constant. Evinacumab-dgnb is not likely to undergo renal excretion.

Evkeeza Interactions

Not Applicable

Evkeeza Adverse Reactions

Adverse Reactions

Nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, nausea, fatigue; hypersensitivity reactions.

Evkeeza Clinical Trials

See Literature

Evkeeza Note

Not Applicable

Evkeeza Patient Counseling

See Literature